Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Wnt signaling and the regulation of bone mass.

Baron R, Rawadi G.

Curr Osteoporos Rep. 2007 Jun;5(2):73-80.

PMID:
17521509
[PubMed - indexed for MEDLINE]
2.

Wnt signaling: a key regulator of bone mass.

Baron R, Rawadi G, Roman-Roman S.

Curr Top Dev Biol. 2006;76:103-27. Review.

PMID:
17118265
[PubMed - indexed for MEDLINE]
3.

The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.

Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W.

Calcif Tissue Int. 2008 Jun;82(6):445-53. doi: 10.1007/s00223-008-9130-9.

PMID:
18521528
[PubMed - indexed for MEDLINE]
4.

Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.

Daoussis D, Andonopoulos AP, Liossis SN.

Semin Arthritis Rheum. 2010 Apr;39(5):369-83. doi: 10.1016/j.semarthrit.2008.10.008. Epub 2008 Dec 18. Review.

PMID:
19095294
[PubMed - indexed for MEDLINE]
5.

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.

van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CW.

J Bone Miner Res. 2007 Jan;22(1):19-28.

PMID:
17032150
[PubMed - indexed for MEDLINE]
6.

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG.

Bone. 2006 Oct;39(4):754-66. Epub 2006 May 26.

PMID:
16730481
[PubMed - indexed for MEDLINE]
7.

The role of the Wnt signaling pathway in osteoblast commitment and differentiation.

Yavropoulou MP, Yovos JG.

Hormones (Athens). 2007 Oct-Dec;6(4):279-94. Review.

PMID:
18055419
[PubMed - indexed for MEDLINE]
Free Article
8.

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.

Baron R, Rawadi G.

Endocrinology. 2007 Jun;148(6):2635-43. Epub 2007 Mar 29. Review.

PMID:
17395698
[PubMed - indexed for MEDLINE]
9.

The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.

Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH.

J Biol Chem. 2006 Aug 18;281(33):23698-711. Epub 2006 Jun 20.

PMID:
16790443
[PubMed - indexed for MEDLINE]
Free Article
10.

[Cytokines in bone diseases. Wnt signal and excessive bone formation].

Hosoi T.

Clin Calcium. 2010 Oct;20(10):1526-31. doi: CliCa101015261531. Review. Japanese.

PMID:
20890035
[PubMed - indexed for MEDLINE]
11.

Expression, purification and functional characterization of Wnt signaling co-receptors LRP5 and LRP6.

Fleury D, Vayssiere B, Touitou R, Gillard C, Lebhar H, Rawadi G, Mollat P.

Protein Expr Purif. 2010 Mar;70(1):39-47. doi: 10.1016/j.pep.2009.08.012. Epub 2009 Aug 27.

PMID:
19716419
[PubMed - indexed for MEDLINE]
12.

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D.

J Biol Chem. 2005 May 20;280(20):19883-7. Epub 2005 Mar 18.

PMID:
15778503
[PubMed - indexed for MEDLINE]
Free Article
13.

The role of Dickkopf-1 in bone development, homeostasis, and disease.

Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr.

Blood. 2009 Jan 15;113(3):517-25. doi: 10.1182/blood-2008-03-145169. Epub 2008 Aug 7. Review.

PMID:
18687985
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

[Wnt/LRP5, a new regulation osteoblastic pathway involved in reaching peak bone masses].

Caverzasio J.

Rev Med Suisse Romande. 2004 Feb;124(2):81-2. French.

PMID:
15095618
[PubMed - indexed for MEDLINE]
15.

[Wnt-beta-catenin signaling in bone metabolism].

Urano T.

Clin Calcium. 2006 Jan;16(1):54-60. Review. Japanese.

PMID:
16397351
[PubMed - indexed for MEDLINE]
16.

Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.

Bhat BM, Allen KM, Liu W, Graham J, Morales A, Anisowicz A, Lam HS, McCauley C, Coleburn V, Cain M, Fortier E, Bhat RA, Bex FJ, Yaworsky PJ.

Gene. 2007 Apr 15;391(1-2):103-12. Epub 2006 Dec 29.

PMID:
17276019
[PubMed - indexed for MEDLINE]
17.

[Recent topics on bone remodeling].

Shinoda Y, Ogata N, Chung UI, Kawaguchi H.

Clin Calcium. 2004 Jan;14(1):70-4. Review. Japanese.

PMID:
15576958
[PubMed - indexed for MEDLINE]
18.

A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists.

Chan A, van Bezooijen RL, Löwik CW.

Curr Opin Investig Drugs. 2007 Apr;8(4):293-8. Review.

PMID:
17458178
[PubMed - indexed for MEDLINE]
19.

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL.

J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:31-5. doi: 10.2106/JBJS.G.01183. Review.

PMID:
18292354
[PubMed - indexed for MEDLINE]
20.

LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.

Levasseur R, Lacombe D, de Vernejoul MC.

Joint Bone Spine. 2005 May;72(3):207-14. Review.

PMID:
15850991
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk